How should empagliflozin be initiated and dosed in patients with chronic kidney disease and reduced estimated glomerular filtration rate, and what monitoring is needed?

Empagliflozin in Kidney Failure: Initiation, Dosing, and Monitoring

Empagliflozin should be initiated at 10 mg once daily in patients with chronic kidney disease and eGFR ≥20 mL/min/1.73 m², and once started, can be continued even as eGFR falls below 20 mL/min/1.73 m² until dialysis initiation. 1

Initiation Criteria

Start empagliflozin when eGFR is ≥20 mL/min/1.73 m², regardless of diabetes status. 1 This represents a significant evolution from older FDA labeling which recommended against initiation below 45 mL/min/1.73 m². 2 The EMPA-KIDNEY trial provided definitive evidence supporting initiation down to eGFR 20 mL/min/1.73 m², demonstrating a 28% reduction in kidney disease progression or cardiovascular death. 3

Specific Patient Populations for Initiation:

• Type 2 diabetes with CKD and eGFR ≥20: Strong recommendation (1A evidence) 1
• CKD with albuminuria ≥200 mg/g and eGFR ≥20: Strong recommendation regardless of diabetes status (1A evidence) 1
• Heart failure with any level of albuminuria and eGFR ≥20: Strong recommendation (1A evidence) 1
• eGFR 20-45 with albuminuria <200 mg/g: Conditional recommendation (2B evidence) 1

Do not initiate if eGFR is persistently <20 mL/min/1.73 m² or if patient is on dialysis. 1, 2

Dosing Strategy

The standard dose is 10 mg once daily, taken in the morning with or without food. 1, 2

Key Dosing Principles:

• No dose adjustment needed for eGFR 30-44 mL/min/1.73 m²: Use 10 mg daily 1
• For eGFR <30 mL/min/1.73 m²: FDA labeling states "use not recommended" for glucose lowering, but current guidelines strongly support 10 mg daily for kidney and cardiovascular protection 1
• The 25 mg dose offers no additional kidney or cardiovascular benefit at lower eGFR levels and is not more effective for glucose lowering in advanced CKD 1

Critical Continuation Principle:

Once initiated, continue empagliflozin even if eGFR falls below the initiation threshold of 20 mL/min/1.73 m², unless not tolerated or dialysis is started. 1 This is based on trial protocols (CREDENCE, DAPA-CKD, EMPA-KIDNEY) that specified continuation below initiation thresholds. 1

Monitoring Requirements

Initial Assessment Before Starting:

• Check eGFR and volume status 1
• Assess for volume depletion risk: elderly patients, low systolic blood pressure, concurrent diuretic use 1
• Review concurrent medications: consider proactive diuretic dose reduction in high-risk patients 1

Expected eGFR Changes:

Expect an acute, reversible 2-6% decline in eGFR within the first 2 months (approximately 2 mL/min/1.73 m² decrease). 4 This initial dip is hemodynamic, not injurious, and should not prompt discontinuation. 1 After this acute phase, empagliflozin reduces the chronic rate of eGFR decline by approximately 50%. 4

Ongoing Monitoring:

• Volume status and blood pressure: Assess at follow-up visits, especially in first weeks after initiation 1
• eGFR monitoring: Continue routine CKD monitoring schedule; initiation does not require more frequent monitoring 1
• Ketone monitoring: Only if symptoms of ketoacidosis develop (nausea, vomiting, abdominal pain, malaise) 1
• Glucose levels: Adjust insulin or sulfonylurea doses if hypoglycemia occurs, but routine adjustment is generally not required 1

Safety Considerations and Risk Mitigation

Volume Depletion:

• Risk is low even at low eGFR, but monitor for symptoms of hypotension 1
• Consider reducing diuretic doses before starting empagliflozin in patients at high risk for volume depletion 1
• Educate patients about symptoms of volume depletion and low blood pressure 1

Ketoacidosis Prevention:

Withhold empagliflozin during prolonged fasting, surgery, or critical illness when ketosis risk is elevated. 1 For insulin-requiring patients, maintain at least low-dose insulin to mitigate ketoacidosis risk. 1 Euglycemic diabetic ketoacidosis can occur with blood glucose <250 mg/dL. 1, 2

Genital Mycotic Infections:

Occur in approximately 6% of patients (vs 1% with placebo), with higher risk in women. 1 Counsel on genital hygiene measures. 1 Most infections are easily treated, though rare severe cases (Fournier gangrene) have been reported. 1

Hypoglycemia:

Absolute risk is low, especially at low eGFR where glucose-lowering efficacy is reduced. 1 Adjustment of background glucose-lowering agents (insulin, sulfonylureas) may be prudent in some patients but is generally not required at initiation. 1

Common Pitfalls to Avoid

1. Do not discontinue for the expected acute eGFR dip in the first 2 months unless creatinine rises >30% 1, 4
2. Do not withhold initiation based solely on low albuminuria: Benefits extend to patients with minimal albuminuria 4, 5
3. Do not stop empagliflozin when eGFR falls below 20 mL/min/1.73 m² if already established on therapy 1
4. Do not rely on outdated FDA labeling that restricts use below eGFR 45 mL/min/1.73 m²; current evidence supports use down to eGFR 20 1, 3
5. Do not forget to pause during acute illness, surgery, or prolonged fasting to reduce ketoacidosis risk 1

Special Populations

Kidney transplant recipients: SGLT2 inhibitors have not been adequately studied in this population due to immunosuppression and infection risk concerns; the recommendation does not apply. 1

Patients without diabetes: The same initiation and monitoring principles apply, as EMPA-KIDNEY demonstrated consistent benefits regardless of diabetes status. 3, 5